{"id":12434,"date":"2024-11-13T14:43:46","date_gmt":"2024-11-13T06:43:46","guid":{"rendered":"https:\/\/flcube.com\/?p=12434"},"modified":"2024-11-13T14:43:49","modified_gmt":"2024-11-13T06:43:49","slug":"schrodinger-and-novartis-ink-deal-to-accelerate-drug-discovery-candidates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12434","title":{"rendered":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates"},"content":{"rendered":"\n

New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR<\/a>), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS<\/a>). This partnership is aimed at advancing multiple development candidates into Novartis’s portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.<\/p>\n\n\n\n

Software Agreement and Technology Deployment<\/strong>
Under the expanded agreement, Novartis will deploy Schr\u00f6dinger\u2019s full suite of drug discovery technologies across its research sites. This includes improved access to Schr\u00f6dinger\u2019s computational predictive modeling technology and enterprise informatics platform, enabling Novartis to operate at an industry-leading scale.<\/p>\n\n\n\n

Financial Terms of the Agreement<\/strong>
The terms of the agreement include an upfront payment of USD 150 million from Novartis to Schr\u00f6dinger. Novartis is also committed to paying USD 892 million in research, development, and regulatory milestone payments. Furthermore, Schr\u00f6dinger is eligible for up to USD 1.38 billion in commercial milestones, along with tiered mid single-digit to low double-digit royalties on net sales of each product commercialized by Novartis.<\/p>\n\n\n\n

Collaboration Responsibilities<\/strong>
Schr\u00f6dinger and Novartis will share responsibility for the discovery of development candidates under the collaboration. Novartis will take the lead on clinical development, manufacturing, and global commercialization of the products.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has…<\/p>\n","protected":false},"author":1,"featured_media":12436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2050,140,865,2049],"class_list":["post-12434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-sdgr","tag-novartis","tag-nyse-nvs","tag-schrodinger"],"yoast_head":"\nSchr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis's portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12434\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12434\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-13T06:43:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-13T06:43:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1312\" \/>\n\t<meta property=\"og:image:height\" content=\"780\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates\",\"datePublished\":\"2024-11-13T06:43:46+00:00\",\"dateModified\":\"2024-11-13T06:43:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow-2024-11-13-14-40-19.png\",\"keywords\":[\"NASDAQ: SDGR\",\"Novartis\",\"NYSE: NVS\",\"Schr\u00f6dinger\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12434#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12434\",\"name\":\"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow-2024-11-13-14-40-19.png\",\"datePublished\":\"2024-11-13T06:43:46+00:00\",\"dateModified\":\"2024-11-13T06:43:49+00:00\",\"description\":\"New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis's portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12434\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow-2024-11-13-14-40-19.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow-2024-11-13-14-40-19.png\",\"width\":1312,\"height\":780,\"caption\":\"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12434#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates - Insight, China's Pharmaceutical Industry","description":"New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis's portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12434","og_locale":"en_US","og_type":"article","og_title":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12434","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-13T06:43:46+00:00","article_modified_time":"2024-11-13T06:43:49+00:00","og_image":[{"width":1312,"height":780,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12434#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12434"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates","datePublished":"2024-11-13T06:43:46+00:00","dateModified":"2024-11-13T06:43:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12434"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=12434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","keywords":["NASDAQ: SDGR","Novartis","NYSE: NVS","Schr\u00f6dinger"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12434#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12434","url":"https:\/\/flcube.com\/?p=12434","name":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=12434#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=12434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","datePublished":"2024-11-13T06:43:46+00:00","dateModified":"2024-11-13T06:43:49+00:00","description":"New York-based Schr\u00f6dinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis's portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12434#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12434"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=12434#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","width":1312,"height":780,"caption":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12434#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Schr\u00f6dinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow-2024-11-13-14-40-19.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12434"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12434\/revisions"}],"predecessor-version":[{"id":12437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12434\/revisions\/12437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/12436"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}